459 related articles for article (PubMed ID: 31049868)
1. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
3. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
4. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
[TBL] [Abstract][Full Text] [Related]
5. Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.
Svensson RJ; Niward K; Davies Forsman L; Bruchfeld J; Paues J; Eliasson E; Schön T; Simonsson USH
Br J Clin Pharmacol; 2019 Oct; 85(10):2341-2350. PubMed ID: 31269277
[TBL] [Abstract][Full Text] [Related]
6. A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.
Svensson RJ; Aarnoutse RE; Diacon AH; Dawson R; Gillespie SH; Boeree MJ; Simonsson USH
Clin Pharmacol Ther; 2018 Apr; 103(4):674-683. PubMed ID: 28653479
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Aarnoutse RE; Kibiki GS; Reither K; Semvua HH; Haraka F; Mtabho CM; Mpagama SG; van den Boogaard J; Sumari-de Boer IM; Magis-Escurra C; Wattenberg M; Logger JGM; Te Brake LHM; Hoelscher M; Gillespie SH; Colbers A; Phillips PPJ; Plemper van Balen G; Boeree MJ;
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827417
[TBL] [Abstract][Full Text] [Related]
8. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
[TBL] [Abstract][Full Text] [Related]
9. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.
de Steenwinkel JE; Aarnoutse RE; de Knegt GJ; ten Kate MT; Teulen M; Verbrugh HA; Boeree MJ; van Soolingen D; Bakker-Woudenberg IA
Am J Respir Crit Care Med; 2013 May; 187(10):1127-34. PubMed ID: 23525933
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
Ekqvist D; Bornefall A; Augustinsson D; Sönnerbrandt M; Nordvall MJ; Fredrikson M; Carlsson B; Sandstedt M; Simonsson USH; Alffenaar JC; Paues J; Niward K
BMJ Open; 2022 Mar; 12(3):e054788. PubMed ID: 35273049
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring in the treatment of tuberculosis: an update.
Alsultan A; Peloquin CA
Drugs; 2014 Jun; 74(8):839-54. PubMed ID: 24846578
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1170-6. PubMed ID: 22250979
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.
Stott KE; Pertinez H; Sturkenboom MGG; Boeree MJ; Aarnoutse R; Ramachandran G; Requena-Méndez A; Peloquin C; Koegelenberg CFN; Alffenaar JWC; Ruslami R; Tostmann A; Swaminathan S; McIlleron H; Davies G
J Antimicrob Chemother; 2018 Sep; 73(9):2305-2313. PubMed ID: 29701775
[TBL] [Abstract][Full Text] [Related]
17. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
[TBL] [Abstract][Full Text] [Related]
18. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
Alsultan A; Savic R; Dooley KE; Weiner M; Whitworth W; Mac Kenzie WR; Peloquin CA;
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289033
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.
Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A
Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]